ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...

At the 2025 IEEE International Electron Devices Meeting (IEDM), research centre Imec is presenting breakthrough performance of p-type FETs with monolayer WSe 2 channels, and improved fab-compatible ...

Beyond Braggin' Rights, the Illini (8-3) will be aiming to rebound from a nerve-wracking loss when they meet their border ...

Victor has gone too far. It’s been said before, but this time, right before Christmas, he has crossed a line too far.

Digital art tools are usually designed to improve control, efficiency, and precision, but this painting software does the exact opposite. In this video, I try one of the most unhinged painting ...

As beauty’s obsession with longevity intensifies, travel is becoming another site of optimization. From hormone-aware ...

After 32 years of waiting, mathematicians calculate Dedekind's ninth number, a 42-digit giant that defied logic.

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...

Investing.com -- Senti Biosciences (NASDAQ:SNTI) stock surged 29% after the company reported positive clinical trial results for its cancer therapy SENTI-202 and received FDA Regenerative Medicine ...

Every nation and organization has the right to determine how its digital resources are governed, protected and shared.

Global sales of total semiconductor manufacturing equipment by original equipment manufacturers (OEMs) are forecast to reach ...